Orlistat

Introduction Overview

Generic Name

orlistat

Brand Name

Alli, Xenical

Dosage Form

oral capsule

Drug Class

Peripherally acting antiobesity agents

Pharmacokinetics

Absorption: Orlistat exhibits minimal systemic absorption when administered orally, with less than 1% bioavailability. Its pharmacological activity is confined primarily to the gastrointestinal tract due to its local effect on digestive enzymes rather than systemic circulation. The drug remains largely within the lumen of the stomach and intestines, exerting its lipid-lowering effect by inhibiting gastrointestinal lipases without entering the bloodstream in significant amounts. This limited absorption minimizes systemic side effects but necessitates administration in close temporal relation to dietary fat intake.

Distribution: Due to the negligible systemic absorption, orlistat does not achieve measurable plasma concentrations, and therefore systemic distribution is not significant. The drug's distribution remains essentially localized within the gastrointestinal tract. Any minimal absorbed amount is rapidly cleared and does not accumulate in body tissues. Consequently, orlistat does not cross the blood-brain barrier or deposit in fatty tissues, consistent with its peripheral site of action.

Metabolism: Orlistat undergoes minimal metabolic transformation due to its confined activity within the gut lumen. Most of the drug is excreted unchanged in the feces. Any absorbed orlistat undergoes rapid hydrolysis to inactive metabolites primarily through hepatic esterases; however, this systemic metabolism is clinically insignificant given the negligible absorption. The parent molecule acts directly in the gastrointestinal lumen to inhibit pancreatic and gastric lipases.

Elimination: The elimination of orlistat occurs predominantly via fecal excretion. Approximately 97% of an administered dose is recovered unchanged in feces within 72 hours, reflecting the local action of the drug. Renal elimination is negligible. The low systemic exposure and fecal elimination minimize systemic adverse effects and drug interactions. The drug's half-life is difficult to define due to minimal absorption but correlates with gastrointestinal transit time. The elimination profile supports dosing thrice daily in relation to meals containing fat to maximize efficacy and minimize side effects.

Dosage Forms

Available Dosage Forms:
- Oral capsules: 120 mg

Dosages for Adults and Adolescents:
- Adults: 120 mg orally three times daily with each main meal containing fat; can be taken during the meal or up to 1 hour after eating.
- Pediatric patients (12 years and older): Same dosing regimen as adults, 120 mg three times daily with meals containing fat; not approved for use under 12 years of age.

Specific Patient Populations:
- Not recommended for use in children under 12 years for prescription formulation (Xenical) and under 18 years for over-the-counter formulation (Alli).
- Use in pregnancy is contraindicated.
- Caution advised in patients with kidney stones, gallbladder disease, pancreatitis, thyroid, liver, or kidney disease, or history of eating disorders such as anorexia or bulimia.
- Patients should adhere to a low-fat diet where fat does not exceed 30% of daily calories to reduce gastrointestinal side effects.
- Vitamin supplementation (fat-soluble vitamins A, D, E, K, and beta-carotene) is recommended, taken at least 2 hours before or after orlistat administration to prevent deficiencies.

Clinical Guidelines:
- To maximize efficacy and avoid adverse gastrointestinal effects, orlistat should be taken with each main meal containing fat, never with snacks or meals devoid of fat.
- Missed doses should be skipped if more than 1 hour has passed since the respective meal.
- Lifestyle interventions including diet and physical activity are critical components of therapy alongside pharmacologic treatment.

Mechanism Of Action

Orlistat is a potent, reversible inhibitor of gastrointestinal lipases, specifically pancreatic lipase and gastric lipase, enzymes responsible for hydrolyzing dietary triglycerides into absorbable free fatty acids and monoglycerides. By covalently binding to the active serine sites on these lipases, orlistat forms a covalent ester bond that blocks the enzymatic cleavage of triglycerides, thereby preventing the breakdown and absorption of approximately 30% of dietary fat in the intestine.

This inhibition leads to an increase in the amount of dietary fat excreted unchanged in the feces, resulting in a reduction of caloric intake and subsequent weight loss when combined with a hypocaloric diet. The blockade of lipase activity primarily occurs in the lumen of the stomach and small intestine, where digestion and absorption of fat normally take place.

At the cellular level, by limiting the availability of free fatty acids for absorption, orlistat influences energy balance and fat storage. This pharmacological action results in decreased fat uptake into adipose tissue and improves metabolic parameters associated with obesity, such as insulin resistance and dyslipidemia. Unlike centrally acting antiobesity agents, orlistat does not affect appetite or central nervous system neurotransmitters, which contributes to its minimal systemic side effect profile.

Clinical studies have demonstrated the efficacy of orlistat in producing modest but sustained weight loss and reducing the risk of weight regain. Its peripheral mechanism also differentiates it from other antiobesity agents, making it useful where centrally acting drugs are contraindicated or poorly tolerated. Research continues on its role in improving obesity-related comorbidities and its impact on body composition over long-term use.

Pharmacological Actions

Inhibition of gastrointestinal lipases (pancreatic and gastric) leading to decreased fat absorption.
Increased excretion of unabsorbed dietary triglycerides in feces resulting in negative energy balance.
Reduction of caloric intake through decreased dietary fat absorption without CNS involvement.
Modulation of lipid metabolism contributing to weight loss and improved lipid profiles.
Facilitation of weight loss when combined with reduced-calorie diet and increased physical activity.
Peripheral site of action limiting systemic adverse effects.
Possible improvement in insulin sensitivity and glycemic control secondary to weight loss.
No significant impact on appetite or central dopamine pathways.
Increased fecal fat excretion mitigates energy uptake from meals.
Reduction of risk factors related to obesity including hypertension, impaired glucose tolerance, and dyslipidemia.
Minimal systemic side effects due to negligible absorption.
Acts independently of thermogenesis or basal metabolic rate changes.
Can improve cardiovascular risk profile in obese or overweight patients with long-term use.
May reduce hepatic steatosis progression by decreasing lipid load.
Demonstrated effectiveness in both adults and adolescents aged 12 years and above.

Therapeutic Or Clinical Uses

Adjunctive treatment for obesity management in adults and adolescents aged 12 years and older.
Facilitation of weight loss in overweight and obese patients (BMI ≥30 kg/m2 or ≥27 kg/m2 with comorbidities).
Maintenance of weight loss and prevention of weight regain after initial weight loss.
Part of a comprehensive weight management program including diet and exercise.
Management of obesity-related comorbidities such as type 2 diabetes, hypertension, and dyslipidemia.
Reduction of cardiovascular risk factors through weight reduction.
Treatment in patients unable to tolerate centrally acting weight loss drugs.
Potential use in nonalcoholic fatty liver disease (NAFLD) adjunct therapy.
Non-prescription use of Alli brand for mild to moderate obesity in adults.
Use in patients who require a peripheral mechanism of action to avoid CNS side effects.
Implementation in weight management plans requiring pharmacological assistance.
Helps mitigate excessive caloric absorption from dietary fats.
Supports healthier lipid profiles through decreased fat absorption.
Approved for use in adults and adolescents but not recommended in children under 12.
Considered for long-term management plans due to safety and tolerability profile.

Side Or Adverse Effects

Oily or fatty stools (steatorrhea) due to undigested fat in feces.
Oily spotting on undergarments or clothing.
Increased bowel movement frequency with possible urgency.
Flatulence with discharge of oily residue.
Fecal incontinence or loose stools.
Abdominal discomfort including pain, cramping, or rectal pain.
Nausea and occasional vomiting.
Headaches reported infrequently.
Possible liver injury, presenting as nausea, upper abdominal pain, pruritus, jaundice, and dark urine, though rare.
Reduction in absorption of fat-soluble vitamins (A, D, E, K) leading to potential deficiencies.
Possible hypoglycemia when co-administered with antidiabetic drugs due to enhanced weight loss effects.
Allergic reactions such as rash, itching, or hives are rare but may occur.
Anal irritation or discomfort due to increased fat content in stool.
Potential kidney stone formation in predisposed individuals due to increased oxalate absorption.
Gastrointestinal symptoms tend to improve with continued use and adherence to low-fat diet.

Precautions

Not to be used during pregnancy; weight loss is contraindicated during pregnancy.
Use cautiously or avoid in patients with a history of malabsorption syndromes.
Evaluate and monitor patients with history of gallbladder disease, pancreatitis, or kidney stones.
Adjust or monitor use in patients with thyroid, liver, or kidney disease.
Assess nutritional status and supplement fat-soluble vitamins during therapy to prevent deficiencies.
Avoid use in patients with organ transplants when taking cyclosporine concurrently due to interaction risks.
Ensure proper dosing only with meals containing fat; skip doses if no fat is consumed to reduce GI adverse effects.
Adherence to therapeutic lifestyle adjustments including a balanced low-fat diet and exercise is essential.
Monitor for signs of liver toxicity such as jaundice or upper abdominal pain during treatment.
Not approved for pediatric patients under 12 years for prescription form or under 18 years for OTC form.
Use with caution in patients with eating disorders due to the potential for misuse.
Patients should inform healthcare providers of all concomitant medications to assess interactions.
Avoid high-fat meals to minimize gastrointestinal side effects and enhance tolerability.
Counsel patients on appropriate vitamin and mineral supplementation timing relative to orlistat intake.
Monitor glycemic control when used concomitantly with hypoglycemic agents to avoid hypoglycemia.

Warnings

Do not use orlistat if pregnant, as weight loss is contraindicated and may harm the fetus.
Avoid use in malabsorption syndrome and chronic malabsorption conditions.
Xenical is contraindicated in patients with gallbladder problems.
Avoid Alli use in non-overweight individuals, those with organ transplant history, or taking cyclosporine.
Take orlistat only with meals containing fat; taking it without fat increases side effect risk without benefit.
Orlistat may cause severe liver injury; discontinue and seek medical attention if symptoms develop.
Do not share medication with others, especially individuals with eating disorders.
High-fat meals may precipitate unpleasant gastro-intestinal side effects including steatorrhea.
Orlistat reduces absorption of fat-soluble vitamins; supplementation is mandatory with proper timing.
Concomitant use with warfarin and other blood thinners requires monitoring for bleeding complications.
Orlistat may affect absorption of immunosuppressants such as cyclosporine; avoid concurrent use or monitor levels.
Safety and effectiveness not established in pediatric patients under 12 years (Xenical) or under 18 years (Alli).
Use cautiously in patients with pre-existing gastrointestinal disorders due to potential exacerbation.
Discontinue therapy if severe gastrointestinal adverse reactions or symptoms of liver damage occur.
Not recommended for use in patients with chronic malabsorptive disorders.

Contraindication

Known hypersensitivity to orlistat or any component of the product.
Pregnancy: weight loss is contraindicated; orlistat use may harm fetal development.
Malabsorption syndrome or chronic gastrointestinal malabsorption conditions.
Use of Xenical is contraindicated in patients with gallbladder disease.
Use of Alli is contraindicated in patients who have had organ transplants.
Concomitant use of Alli in patients on cyclosporine therapy due to interaction and absorption concerns.
Non-overweight individuals should not use Alli for weight loss.
History of cholestasis or severe hepatic disease.
Children under 12 years of age (Xenical) or under 18 years (Alli) due to lack of safety and efficacy data.
Active acute malabsorption or chronic malabsorptive disorders such as cystic fibrosis.
Patients with chronic malnutrition or pre-existing fat-soluble vitamin deficiencies without appropriate supplementation.
Patients with severe renal impairment have not been specifically studied; caution advised.
Avoid in patients with known hypersensitivity to any drug class related to lipase inhibitors.
Contraindicated in patients with history of chronic diarrhea or inflammatory bowel disease without medical supervision.
Not recommended in patients with active pancreatitis or severe gastrointestinal disease.

Drug Interactions

Cyclosporine: Orlistat reduces cyclosporine absorption; avoid concurrent use or separate dosing by at least 3 hours with monitoring.
Warfarin and other anticoagulants: Orlistat may increase the risk of bleeding; monitor INR and adjust dosage accordingly.
Levothyroxine: Orlistat may interfere with absorption; separate doses by at least 4 hours and monitor thyroid function.
Amiodarone: Possible alterations in bioavailability; use caution and monitor therapeutic effect.
Antidiabetic drugs (insulin or oral hypoglycemics): Enhanced glucose control may occur; monitor for hypoglycemia.
HIV or AIDS medications: Possible changes in absorption and plasma concentrations; monitor therapy closely.
Seizure medications: The efficacy may be affected if serum levels decrease; monitor for seizure control.
Beta-carotene or vitamin E supplements: Orlistat decreases absorption; supplementation timing should be adjusted.
Fat-soluble vitamins (A, D, E, K): Absorption decreased; vitamin supplementation recommended at separate times.
Oral contraceptives: Theoretically decreased absorption due to fat malabsorption; counsel on alternative contraception if diarrhea occurs.
Other lipase inhibitors or gastrointestinal motility agents: May potentiate gastrointestinal adverse reactions.
Medications requiring adequate fat absorption may have reduced efficacy.
Herbal supplements affecting fat absorption or metabolism could alter orlistat’s effectiveness or tolerability.
Drugs metabolized in liver are unlikely to be affected due to minimal systemic absorption of orlistat.
Interaction potential is highest when medications have narrow therapeutic indices and rely on fat absorption.

Preparations Of The Drug

Oral capsules containing 120 mg of orlistat for prescription use (Xenical).
Over-the-counter oral capsules containing 60 mg orlistat branded as Alli (variable by country/region).
Capsules available in bottles for oral administration, typically dispensed as 30, 60, or 120 capsules per pack.
Standard formulation is designed for administration three times daily with main meals containing fat.
No intravenous or other non-oral preparations commercially available or approved.
Available in blister packs or bottles with child-resistant closures.
Packaging includes dosage instructions emphasizing administration with fat-containing meals.
Vitamin and mineral combination supplements recommended for concurrent use, but sold separately.
Generic formulations available in various markets, meeting FDA and local regulatory standards.
Storage instructions specify room temperature storage away from moisture, heat, and light.
Imprint codes and capsule colors vary among manufacturers for identification.
Supplied as hard gelatin capsules intended for oral administration only.
Special formulations for pediatric use are not available; dosing is per adult capsule adjusted for age ≥12 years.
Supplements with fat-soluble vitamins recommended to use at bedtime or spaced ≥2 hours from orlistat dose.
No combination preparation with other weight loss agents; orlistat is used as monotherapy adjunct.